Vaxart Q1 2025: $228M Assets, $0.4M Liabilities
Ticker: VXRT · Form: 10-Q · Filed: May 13, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, 10-Q, biotech
TL;DR
Vaxart Q1 2025: $228M assets, $0.4M liabilities, $227.8M cash. Solid financials.
AI Summary
Vaxart, Inc. filed its Q1 2025 10-Q report on May 13, 2025, for the period ending March 31, 2025. The company reported total assets of $228.2 million and total liabilities of $0.4 million. Vaxart's cash and cash equivalents stood at $227.8 million as of March 31, 2025.
Why It Matters
This filing provides a snapshot of Vaxart's financial health at the end of the first quarter of 2025, indicating a strong cash position relative to its liabilities.
Risk Assessment
Risk Level: low — The filing shows a very low level of liabilities compared to assets, suggesting minimal financial risk from debt.
Key Numbers
- $228.2B — Total Assets (Represents the company's total resources as of March 31, 2025.)
- $0.4M — Total Liabilities (Indicates the company's total obligations as of March 31, 2025.)
- $227.8M — Cash and Cash Equivalents (Shows the company's readily available funds as of March 31, 2025.)
- 5,000,000 — Common Stock Shares Outstanding (Number of common shares outstanding as of March 31, 2025.)
Key Players & Entities
- Vaxart, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250513 (date) — Filing date of the report
- $228.2 million (dollar_amount) — Total assets as of March 31, 2025
- $0.4 million (dollar_amount) — Total liabilities as of March 31, 2025
- $227.8 million (dollar_amount) — Cash and cash equivalents as of March 31, 2025
FAQ
What was Vaxart's total revenue for the first quarter of 2025?
The filing does not explicitly state total revenue for the first quarter of 2025, but it does mention 'NonCashRoyaltyRevenueMember' for the periods ending March 31, 2025, and March 31, 2024.
What is the company's reported net loss for the period ending March 31, 2025?
The filing indicates a net loss of $702,776 for the three months ended March 31, 2025.
How much did Vaxart spend on research and development in Q1 2025?
The filing shows $429,547 in research and development expenses for the three months ended March 31, 2025.
What were Vaxart's general and administrative expenses for the first quarter of 2025?
General and administrative expenses for the three months ended March 31, 2025, were $227,550.
What is the par value of Vaxart's common stock?
The par value of Vaxart's common stock is $0.0001 per share.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Vaxart, Inc. (VXRT).